Aardvark released exploratory data from its stopped Phase 3 HERO trial in Prader-Willi syndrome after FDA lifted the hold, and plans a redesigned Phase 3.
|Articles|July 6, 2017
Gustave Roussy Selects TrialMaster EDC to Support Cancer Research
Advertisement
FORT LAUDERDALE, FL., July 05, 2017 (GLOBE NEWSWIRE)-Gustave Roussy, the cancer research institute in Europe, has selected TrialMaster electronic data capture (EDC) technology from OmniComm Systems, Inc., a global provider of clinical data management technology. OmniComm’s TrialMaster will support Gustave Roussy-sponsored clinical trials in oncology that are handled and analyzed by Gustave Roussy’s biostatistics and epidemiology unit. Gustave Roussy focuses on patient care, research, and teaching for all types of cancer.
TrialMaster was chosen because of certain features, including the ability to build studies, adeptness in query management workflow, intuitive interface, monitoring and centralized source review, eLearning modules, exporting abilities, and the range of report types.
“To have an institution as prestigious as Gustave Roussy select TrialMaster is a real testament to the quality, flexibility and scalability of both our EDC technology and our business operations. Moreover, we are incredibly proud to have been selected as their EDC partner,” said Kuno van der Post, OmniComm’s chief commercial officer. “TrialMaster has seen a great deal of well-publicized success over the last 18 months within the academic sector. Coupled with our deployments over that same time period in both pharmacompanies and CROs, it adds up to an achievement that cannot be emulated by many of the EDC systems available today.”
Contact Info
Kuno van der Post
OmniComm Systems, Inc.
+1.954.473.1254
KVanderPost@omnicomm.com
Advertisement
Related to this article
Clinical trials capture data faster than ever, but the real bottleneck is the distance between data capture and a decision teams can trust.
In today’s ACT Brief, we examine why the future of AI in trials is a trusted orchestration system rather than a single model, how coordinators rate eSource-enabled workflows, and what a bipartisan bill proposes for reusable trial networks.
The Faster Clinical Trials Act would create an FDA Center for Clinical Trial Innovation and aims to cut trial costs and enrollment time by at least 30%.
Standardized measurement across five oncology centers found that clinical research coordinators rated eSource-enabled workflows positively (Overall Mean Satisfaction 5.79 of 7), with reduced manual entry and electronic data transfer earning strong marks, while perceived reduction in sponsor and monitor queries lagged as the one domain below threshold.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, describes the industry’s trajectory toward a unified intelligence orchestration environment—and explains why the future isn’t one model that knows everything, but a trusted system that brings the right evidence to the right human decision.
In today’s ACT Brief, we examine how sites can avoid both fear-driven and overly aggressive AI adoption, why community-based research needs sustained financial investment, and why patient access matters more than organizational size.
Pacing obesity trial enrollment, anchoring eligibility to stable real-world therapies, and building site and physician relationships improve retention and data quality more than aggressive recruitment or restrictive exclusion criteria do.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Building Standardized Evidence for eSource-Enabled Clinical Trials: Multi-Site Validation of a Clinical Research Coordinator Satisfaction Methodology
2
Bipartisan Bill Would Build Reusable Clinical Trial Networks, With a Focus on Rare Disease
3
Where the Industry Is Headed as Clinical, Operational, and Real-World Data Connect
4
Where AI Governance in Clinical Development Falls Short
5